001     130669
005     20240228143452.0
024 7 _ |a 10.1093/neuonc/nov322
|2 doi
024 7 _ |a pmid:26826203
|2 pmid
024 7 _ |a pmc:PMC4864264
|2 pmc
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a altmetric:5063745
|2 altmetric
037 _ _ |a DKFZ-2017-05747
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Thomas, Christian
|b 0
245 _ _ |a Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups.
260 _ _ |a Oxford
|c 2016
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1522147754_11125
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Choroid plexus tumors are intraventricular neoplasms derived from the choroid plexus epithelium. A better knowledge of molecular factors involved in choroid plexus tumor biology may aid in identifying patients at risk for recurrence.Methylation profiles were examined in 29 choroid plexus papillomas (CPPs, WHO grade I), 32 atypical choroid plexus papillomas (aCPPs, WHO grade II), and 31 choroid plexus carcinomas (CPCs, WHO grade III) by Illumina Infinium HumanMethylation450 Bead Chip Array.Unsupervised hierarchical clustering identified 3 subgroups: methylation cluster 1 (pediatric CPP and aCPP of mainly supratentorial location), methylation cluster 2 (adult CPP and aCPP of mainly infratentorial location), and methylation cluster 3 (pediatric CPP, aCPP, and CPC of supratentorial location). In methylation cluster 3, progression-free survival (PFS) accounted for a mean of 72 months (CI, 55-89 mo), whereas only 1 of 42 tumors of methylation clusters 1 and 2 progressed (P< .001). On stratification of outcome data according to WHO grade, all CPCs clustered within cluster 3 and were associated with shorter overall survival (mean, 105 mo [CI, 81-128 mo]) and PFS (mean, 55 mo [CI, 36-73 mo]). The aCPP of methylation cluster 3 also progressed frequently (mean, 69 mo [CI, 44-93 mo]), whereas no tumor progression was observed in aCPP of methylation clusters 1 and 2 (P< .05). Only 1 of 29 CPPs recurred.Methylation profiling of choroid plexus tumors reveals 3 distinct subgroups (ie, pediatric low-risk choroid plexus tumors [cluster 1], adult low-risk choroid plexus tumors [cluster 2], and pediatric high-risk choroid plexus tumors [cluster 3]) and may provide useful prognostic information in addition to histopathology.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Sill, Martin
|0 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
|b 1
|u dkfz
700 1 _ |a Ruland, Vincent
|b 2
700 1 _ |a Witten, Anika
|b 3
700 1 _ |a Hartung, Stefan
|b 4
700 1 _ |a Kordes, Uwe
|b 5
700 1 _ |a Jeibmann, Astrid
|b 6
700 1 _ |a Beschorner, Rudi
|b 7
700 1 _ |a Keyvani, Kathy
|b 8
700 1 _ |a Bergmann, Markus
|b 9
700 1 _ |a Mittelbronn, Michel
|0 P:(DE-He78)3494efbbc54460b109fe9eab0595adda
|b 10
|u dkfz
700 1 _ |a Pietsch, Torsten
|b 11
700 1 _ |a Felsberg, Jörg
|b 12
700 1 _ |a Monoranu, Camelia M
|b 13
700 1 _ |a Varlet, Pascale
|b 14
700 1 _ |a Hauser, Peter
|b 15
700 1 _ |a Olar, Adriana
|b 16
700 1 _ |a Grundy, Richard G
|b 17
700 1 _ |a Wolff, Johannes E
|b 18
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 19
|u dkfz
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 20
|u dkfz
700 1 _ |a Bewerunge-Hudler, Melanie
|0 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
|b 21
|u dkfz
700 1 _ |a Hovestadt, Volker
|0 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
|b 22
|u dkfz
700 1 _ |a von Deimling, Andreas
|b 23
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 24
|u dkfz
700 1 _ |a Paulus, Werner
|b 25
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 26
|u dkfz
700 1 _ |a Hasselblatt, Martin
|b 27
773 _ _ |a 10.1093/neuonc/nov322
|g Vol. 18, no. 6, p. 790 - 796
|0 PERI:(DE-600)2094060-9
|n 6
|p 790 - 796
|t Neuro-Oncology
|v 18
|y 2016
|x 1523-5866
909 C O |o oai:inrepo02.dkfz.de:130669
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)3494efbbc54460b109fe9eab0595adda
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)7999346780553d7fab7ba69d5afdfa71
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 26
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEURO-ONCOLOGY : 2015
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)W110-20160331
|k W110
|l Microarray Unit
|x 3
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l Molekulare Genetik
|x 4
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 5
920 1 _ |0 I:(DE-He78)L501-20160331
|k L501
|l DKTK Frankfurt
|x 6
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)W110-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L501-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21